- Home
- Publications
- Publication Search
- Publication Details
Title
Sensing damage by the NLRP3 inflammasome
Authors
Keywords
-
Journal
IMMUNOLOGICAL REVIEWS
Volume 243, Issue 1, Pages 152-162
Publisher
Wiley
Online
2011-09-05
DOI
10.1111/j.1600-065x.2011.01043.x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cutting Edge: Alum Adjuvant Stimulates Inflammatory Dendritic Cells through Activation of the NALP3 Inflammasome
- (2014) M. Kool et al. JOURNAL OF IMMUNOLOGY
- Cutting Edge: Inflammasome Activation by Alum and Alum's Adjuvant Effect Are Mediated by NLRP3
- (2014) H. Li et al. JOURNAL OF IMMUNOLOGY
- Inflammasome Activation of Cardiac Fibroblasts Is Essential for Myocardial Ischemia/Reperfusion Injury
- (2011) Masanori Kawaguchi et al. CIRCULATION
- Hyperglycemia Activates Caspase-1 and TXNIP-Mediated IL-1 Transcription in Human Adipose Tissue
- (2011) T. B. Koenen et al. DIABETES
- Unknown
- (2011) Alexander Moschen et al. MOLECULAR MEDICINE
- The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance
- (2011) Bolormaa Vandanmagsar et al. NATURE MEDICINE
- Atherosclerosis in ApoE-deficient mice progresses independently of the NLRP3 inflammasome
- (2011) P Menu et al. Cell Death & Disease
- Interleukin-1 Blockade With Anakinra to Prevent Adverse Cardiac Remodeling After Acute Myocardial Infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot Study)
- (2010) Antonio Abbate et al. AMERICAN JOURNAL OF CARDIOLOGY
- Why not treat human cancer with interleukin-1 blockade?
- (2010) Charles A. Dinarello CANCER AND METASTASIS REVIEWS
- The Inflammasome-Mediated Caspase-1 Activation Controls Adipocyte Differentiation and Insulin Sensitivity
- (2010) Rinke Stienstra et al. Cell Metabolism
- Interleukin-1β modulation using a genetically engineered antibody prevents adverse cardiac remodelling following acute myocardial infarction in the mouse
- (2010) Antonio Abbate et al. EUROPEAN JOURNAL OF HEART FAILURE
- The NLRP3 inflammasome, a target for therapy in diverse disease states
- (2010) Graham P. Cook et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Inflammasomes as microbial sensors
- (2010) Luigi Franchi et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Targeting IL-1β in disease; the expanding role of NLRP3 inflammasome
- (2010) Ioannis Mitroulis et al. European Journal of Internal Medicine
- Canakinumab: a human anti-IL-1β monoclonal antibody for the treatment of cryopyrin-associated periodic syndromes
- (2010) Leigh D Church et al. Expert Review of Clinical Immunology
- Gene Silencing of NALP3 Protects Against Liver Ischemia–Reperfusion Injury in Mice
- (2010) Ping Zhu et al. HUMAN GENE THERAPY
- An Inflammasome-Independent Role for Epithelial-Expressed Nlrp3 in Renal Ischemia-Reperfusion Injury
- (2010) A. A. Shigeoka et al. JOURNAL OF IMMUNOLOGY
- TLR4 Promotes Fibrosis but Attenuates Tubular Damage in Progressive Renal Injury
- (2010) W. P. Pulskens et al. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY
- TLR2 and TLR4 in Ischemia Reperfusion Injury
- (2010) F. Arslan et al. MEDIATORS OF INFLAMMATION
- A role for mitochondria in NLRP3 inflammasome activation
- (2010) Rongbin Zhou et al. NATURE
- NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals
- (2010) Peter Duewell et al. NATURE
- Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 inflammasome
- (2010) Kiichi Nakahira et al. NATURE IMMUNOLOGY
- Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1β in type 2 diabetes
- (2010) Seth L Masters et al. NATURE IMMUNOLOGY
- IL-1 pathways in inflammation and human diseases
- (2010) Cem Gabay et al. Nature Reviews Rheumatology
- Cholesterol Crystals Activate the NLRP3 Inflammasome in Human Macrophages: A Novel Link between Cholesterol Metabolism and Inflammation
- (2010) Kristiina Rajamäki et al. PLoS One
- The interleukin 1 inhibitor rilonacept in treatment of chronic gouty arthritis: results of a placebo-controlled, monosequence crossover, non-randomised, single-blind pilot study
- (2009) R Terkeltaub et al. ANNALS OF THE RHEUMATIC DISEASES
- The Inflammasomes: Guardians of the Body
- (2009) Fabio Martinon et al. Annual Review of Immunology
- Sensing pathogens and danger signals by the inflammasome
- (2009) Joao HF Pedra et al. CURRENT OPINION IN IMMUNOLOGY
- Sustained Effects of Interleukin-1 Receptor Antagonist Treatment in Type 2 Diabetes
- (2009) C. M. Larsen et al. DIABETES CARE
- CA-074Me Protection against Anthrax Lethal Toxin
- (2009) Z. L. Newman et al. INFECTION AND IMMUNITY
- Alum Induces Innate Immune Responses through Macrophage and Mast Cell Sensors, But These Sensors Are Not Required for Alum to Act As an Adjuvant for Specific Immunity
- (2009) A. S. McKee et al. JOURNAL OF IMMUNOLOGY
- AIM2 activates the inflammasome and cell death in response to cytoplasmic DNA
- (2009) Teresa Fernandes-Alnemri et al. NATURE
- AIM2 recognizes cytosolic dsDNA and forms a caspase-1-activating inflammasome with ASC
- (2009) Veit Hornung et al. NATURE
- An orthogonal proteomic-genomic screen identifies AIM2 as a cytoplasmic DNA sensor for the inflammasome
- (2009) Tilmann Bürckstümmer et al. NATURE IMMUNOLOGY
- Thioredoxin-interacting protein links oxidative stress to inflammasome activation
- (2009) Rongbin Zhou et al. NATURE IMMUNOLOGY
- The Role of Toll-Like Receptor 2 in Inflammation and Fibrosis during Progressive Renal Injury
- (2009) Jaklien C. Leemans et al. PLoS One
- Necrotic cells trigger a sterile inflammatory response through the Nlrp3 inflammasome
- (2009) S. S. Iyer et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- HIN-200 Proteins Regulate Caspase Activation in Response to Foreign Cytoplasmic DNA
- (2009) T. L. Roberts et al. SCIENCE
- TOLL-LIKE RECEPTORS IN ISCHEMIA-REPERFUSION INJURY
- (2009) Thiruma V. Arumugam et al. SHOCK
- Active Caspase-1 Is a Regulator of Unconventional Protein Secretion
- (2008) Martin Keller et al. CELL
- Anakinra, a Recombinant Human Interleukin-1 Receptor Antagonist, Inhibits Apoptosis in Experimental Acute Myocardial Infarction
- (2008) Antonio Abbate et al. CIRCULATION
- The Nlrp3 inflammasome is critical for aluminium hydroxide-mediated IL-1β secretion but dispensable for adjuvant activity
- (2008) Luigi Franchi et al. EUROPEAN JOURNAL OF IMMUNOLOGY
- Rapid appearance and local toxicity of amyloid-β plaques in a mouse model of Alzheimer’s disease
- (2008) Melanie Meyer-Luehmann et al. NATURE
- Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants
- (2008) Stephanie C. Eisenbarth et al. NATURE
- Cancer-related inflammation
- (2008) Alberto Mantovani et al. NATURE
- Critical function for Naip5 in inflammasome activation by a conserved carboxy-terminal domain of flagellin
- (2008) Karla L Lightfield et al. NATURE IMMUNOLOGY
- Superoxide dismutase 1 regulates caspase-1 and endotoxic shock
- (2008) Felix Meissner et al. NATURE IMMUNOLOGY
- Silica crystals and aluminum salts activate the NALP3 inflammasome through phagosomal destabilization
- (2008) Veit Hornung et al. NATURE IMMUNOLOGY
- The NALP3 inflammasome is involved in the innate immune response to amyloid-β
- (2008) Annett Halle et al. NATURE IMMUNOLOGY
- Toll-Like Receptor-4 Coordinates the Innate Immune Response of the Kidney to Renal Ischemia/Reperfusion Injury
- (2008) Wilco P. Pulskens et al. PLoS One
- The Nalp3 inflammasome is essential for the development of silicosis
- (2008) Suzanne L. Cassel et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Innate Immune Activation Through Nalp3 Inflammasome Sensing of Asbestos and Silica
- (2008) C. Dostert et al. SCIENCE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More